<DOC>
	<DOCNO>NCT00031668</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . It yet know give radiation therapy stem cell transplantation effective stem cell transplantation alone treat relapsed refractory non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial determine effectiveness radiation therapy treat patient relapsed refractory non-Hodgkin 's lymphoma undergone autologous stem cell transplantation .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma Who Have Undergone Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : - Compare 3-year progression-free survival patient relapse refractory aggressive non-Hodgkin 's lymphoma treat high-dose chemotherapy autologous hematopoietic stem cell transplantation without involved-field radiotherapy . - Compare overall survival patient treat regimen . - Compare 3-year progression-free disease within outside radiotherapy field patient treat regimen . - Compare quality life patient treat regimen . - Compare toxic effect regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord response pre-salvage chemotherapy ( primary refractory disease v relapse ) , response post-salvage chemotherapy ( complete/unconfirmed complete v partial ) , participate center . Within 6-8 week completion autologous hematopoietic stem cell transplantation , patient randomize 1 2 treatment arm . - Arm I : Patients undergo involved-field radiotherapy ( IFRT ) 5 day week 3-5 week absence unacceptable toxicity . - Arm II : Patients undergo observation . Quality life arm I assess baseline , day 1 IFRT , week 2 4 IFRT , 1 month , 4 month , every 3 month 2 year , every 6 month 1 year , annually 2 year . Quality life arm II assess baseline , 1 month , 2 month , every 3 month 2 year , every 6 month 1 year , annually 2 year . Patients follow 1 month , every 3 month 2 year , every 6 month 1 year , annually 2 year . PROJECTED ACCRUAL : A total 230 patient ( 115 per treatment arm ) accrue study within 4.2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonHodgkin 's lymphoma Diffuse large cell lymphoma , Bcell ( include primary mediastinal Bcell lymphoma Tcell rich Bcell lymphoma ) Previous indolent lymphoma ( follicular center cell lymphoma , marginal zone lymphoma , include extranodal MALT lymphoma lymphoplasmacytoid lymphoma ) transformation diffuse large Bcell lymphoma relapse Peripheral Tcell lymphoma Anaplastic large cell lymphoma ( T cell null cell ) Small noncleaved Burkittlike lymphoma Relapsed refractory disease firstline anthracyclinebased chemotherapy Bulky disease , nodal extranodal Clinically radiographically measurable mass least 5 cm diameter OR Nonbulky disease , nodal extranodal , exclude diffuse organ ( lung , liver , kidney , bone marrow ) involvement Clinically radiographically measurable disease 1.5 cm great transverse diameter Biopsy relapse require except transformed lymphoma Patients transform lymphoma diagnosis , indolent histology without transformation relapse , eligible No patient stage IA IIA disease initial diagnosis , time relapse diagnosis refractory disease prior salvage therapy , remain stage IA IIA , new disease site , without receive radiotherapy Received 2 regimen 4 course salvage chemotherapy Monoclonal antibody ( e.g. , rituximab ) consider salvage chemotherapy Achieved complete response ( CR ) , unconfirmed CR , partial response ( PR ) bulky disease OR Achieved PR ( CR ) nonbulky disease No residual disease involve extranodal organ diffusely ( e.g. , liver , lung , bone , kidney , leptomeningeal ) salvage chemotherapy Planned autologous hematopoietic stem cell transplantation ( ASCT ) ASCT condition must highdose BEAM ( carmustine , etoposide , cytarabine , melphalan ) chemotherapy No disease progression ASCT No major organ complication poor hematologic recovery ASCT would preclude initiation study radiotherapy within 14 week ASCT No 2 noncontiguous nodal extranodal area bulky/residual disease require 2 separate involvedfield radiotherapy volume arrangement ( e.g. , field arrangement cover 2 involved lymph node region extranodal site , without 1 adjacent nodal/region extranodal site ) No active CNS lymphoma ( parenchymal brain and/or leptomeningeal ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except basal cell carcinoma skin PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior radioimmunotherapy Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior total body irradiation No prior radiotherapy site bulky disease residual tumor Surgery : Not specify Other : No concurrent anticancer therapy unless documentation disease progression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>